Portfolio Companies – Page 26 – BioScience Managers

Rex Bionics inks US Army deal to test robot exoskeletons with amputees

16th May 2016/in Rex Bionics

https://www.stuff.co.nz/business/better-business/78700698/Rex-Bionics-inks-US-Army-deal-to-test-robot-exoskeletons-with-amputees Auckland robotics company Rex Bionics has signed a deal with the United States Army to help amputee soldiers get back on their feet. The special agreement means the firm, which develops robotic suits and legs, will be able to test out its developing “Rex Suit” technology on hundreds of maimed veterans Rex Bionics has spent many years and millions […]

AmpliPhi Biosciences Reports First Quarter 2016 Financial Results and Provides Corporate Update

12th May 2016/in Portfolio Companies

SAN DIEGO, May 12, 2016 – Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced its financial results for the first quarter ended March 31, 2016. “We have made significant progress in 2016, effectively executing on our clinical development and business […]

Nexvet Reports Financial Results for Third Quarter of Fiscal Year 2016

12th May 2016/in Portfolio Companies

DUBLIN, Ireland, May 12, 2016 (GLOBE NEWSWIRE) — Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced its financial results for the three and nine-month periods ended March 31, 2016. Recent company highlights include: Advanced clinical development and regulatory preparations for ranevetmab (NV-01), for the control of pain associated with osteoarthritis in dogs […]

Avita’s ReNovaCell™ Offers Advantages in Skin Repigmentation of Burn Scars

9th May 2016/in Portfolio Companies

Northridge, CA, Perth, Australia and Cambridge, UK, 9 May 2016. Link here.

Avita Medical’s ReCell Technology Demonstrated at Vitiligo Conferences in China

3rd May 2016/in Portfolio Companies

Northridge, CA, USA, Perth, Australia and Cambridge, United Kingdom, 3 May 2016 – Link here.

Nexvet and Zenoaq Announce PD-1 mAb Candidate for Canine Cancer & USDA Regulatory Jurisdiction Confirmed

2nd May 2016/in Portfolio Companies

DUBLIN, Ireland, May 02, 2016 (GLOBE NEWSWIRE) – Link here – Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, and Zenoaq (Nippon Zenyaku Kogyo Co., Ltd.), a leading Japanese animal health company, announced today their research and development collaboration has yielded fully caninized, or ‘100% dog’, monoclonal antibodies (mAbs) that bind and potently inhibit the immuno-oncology […]

Avita Medical – Shareholder Letter

29th April 2016/in Portfolio Companies

29 April, 2016. Link here.

SeaDragon – Market Update

26th April 2016/in Portfolio Companies, SeaDragon

NZX / MEDIA RELEASE 26 April 2016. Link here. Omega-3 update; Omega-2 sales slow; Revised financial guidance SeaDragon Limited (NZX:SEA) is pleased to update the market on the following recent events. Omega-3 Refinery As previously noted to the market, the commissioning of SeaDragon’s new Omega-3 refinery has been successfully completed, with the plant meeting performance […]